News Release 

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

Oncotarget Volume 11, Issue 4: In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin -- radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}

Impact Journals LLC

IMAGE

IMAGE: Kaplan Meier estimates of progression-free survival between the 2 arms. view more 

Credit: Correspondence to - Kumar Prabhash - kumarprabhashtmh@gmail.com

Oncotarget Volume 11, Issue 4: In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin - radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}.

An interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes.

We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm.

The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers.

Dr. Kumar Prabhash from the Department of Medical Oncology at the Tata Memorial Hospital, HBNI in Mumbai India said in their Oncotarget research article, "Locally advanced oropharyngeal cancers possess a unique challenge."

Patients with HPV positive disease have a favorable prognosis as opposed to HPV negative disease.

They had hypothesized that an improvement in outcomes in our study was seen due to the differential patient population in our study when compared to the RTOG 0552 study.

Another phase 3 study, exploring the role of cetuximab along with carboplatin -5 FU with radiation, reported improvement in outcomes with the addition of cetuximab.

Taking this into consideration, the authors decided to perform a subgroup analysis of the HPV negative oropharyngeal cancer cohort, to study the absolute improvement in 2-year outcomes with the addition of nimotuzumab.

The Prabhash Research Team concluded in their Oncotarget article that an interaction test was performed prior to doing the subgroup analysis, to determine whether nimotuzumab had a differential impact or not.

###

Sign up for free Altmetric alerts about this article

Full text - https://doi.org/10.18632/oncotarget.27443

Correspondence to - Kumar Prabhash - kumarprabhashtmh@gmail.com

Keywords - HPV negative, oropharynx, nimotuzumab, weekly, cisplatin

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @Oncotarget

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105
MEDIA@IMPACTJOURNALS.COM

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.